Heidi Cuthbert

Southern Cross Electrical Engineering lifts FY26 guidance to $72m despite a $12.8m H1 loss driven by WestConnex arbitration costs.

Dyno Nobel (ASX:DNL) has finalised its strategic exit from the fertiliser sector by entering into a binding agreement to sell its Phosphate Hill asset to Ryowa II GPS.

SRJ Technologies Group (ASX:SRJ) has bolstered its presence in the Middle East after signing a key service level agreement with UAE-based Gecko Middle East Petroleum.

Precision BioSciences (NASDAQ:DTIL) shares are in focus after the U.S. Food and Drug Administration granted Fast Track designation to PBGENE-DMD, an investigational in vivo gene editing therapy designed to treat Duchenne muscular dystrophy (DMD).

American Express Global Business Travel (NYSE:GBTG) reported a transformative fourth quarter on Monday, as the integration of recent acquisition CWT propelled revenue up 34% to $792 million.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) reported a fourth-quarter loss that was narrower than analysts anticipated, bolstered by a significant cash injection and clinical progress in its high-priority obesity and oncology programs.

3D Systems (NYSE:DDD) reported a fourth-quarter loss that underscored the ongoing volatility in the industrial manufacturing sector, even as the company saw a double-digit jump in sequential sales.

Pfizer announced positive topline results for its investigational trispecific antibody, tilrekimig, which demonstrated significant skin clearance in adults with moderate to severe eczema and paved the way for a pivotal Phase 3 study later this year.

IDEAYA Biosciences reached a key clinical milestone on Monday, dosing the first patient in its Phase 1 trial for IDE892, a potential best-in-class PRMT5 inhibitor designed to target MTAP-deleted solid tumors.

XRP investors are currently holding approximately $50.8 billion in unrealised losses after the token’s sharp decline from its 2025 peak, according to blockchain analytics firm Glassnode.